外科理论与实践 ›› 2023, Vol. 28 ›› Issue (06): 501-506.doi: 10.16139/j.1007-9610.2023.06.03
收稿日期:
2023-11-06
出版日期:
2023-11-25
发布日期:
2024-03-04
通讯作者:
刘志艳,E-mail:zhiyanliu@shsmu.edu.cn
基金资助:
LIU Zhiyan1(), YU Yaling1, KAKUDO Kennichi2
Received:
2023-11-06
Online:
2023-11-25
Published:
2024-03-04
摘要:
甲状腺髓样癌(medullary thyroid carcinoma, MTC)侵袭性强,转移率、复发率高,在甲状腺恶性肿瘤中相对少见。手术治疗是MTC首选治疗方案,靶向和免疫治疗已逐渐成为MTC新型治疗模式。2022年,第5版世界卫生组织内分泌与神经内分泌肿瘤分类对MTC进行组织学分级,并更新其分子病理特征。本文阐述MTC病理诊断新进展,并着重于组织学分级系统、分子特征和遗传筛查与咨询在MTC复发风险分层及靶向治疗方面的关键作用。
中图分类号:
刘志艳, 余雅玲, 觉道健一. 甲状腺髓样癌病理诊断新进展[J]. 外科理论与实践, 2023, 28(06): 501-506.
LIU Zhiyan, YU Yaling, KAKUDO Kennichi. Update of pathology in medullary thyroid carcinoma[J]. Journal of Surgery Concepts & Practice, 2023, 28(06): 501-506.
[1] | 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会甲状腺髓样癌诊疗指南2022[M]. 人民卫生出版社, 2022. |
Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology Diagnosis and Treatment guidelines: myeloid thyroid cancer 2022[M]. People's Health Publishing House, 2022. | |
[2] | 刘志艳, 刘书佚, 王馨培, 等. 第5版WHO甲状腺滤泡源性肿瘤分类解读[J]. 中华病理学杂志, 2023, 52(1):7-12. |
LIU Z Y, LIU S Y, WANG X P, et al. Interpretation of WHO classification of thyroid follicular tumors, 5th edition[J]. Chin J Path, 2023, 52(1):7-12. | |
[3] | 甲状腺细针穿刺细胞病理学诊断专家共识编写组, 中华医学会病理学分会细胞病理学组. 甲状腺细针穿刺细胞病理学诊断专家共识(2023版)[J]. 中华病理学杂志, 2023, 52(5):441-446. |
Expert Consensus Writing Group for Thyroid Fine Needle aspiration cytopathology, Cytopathology Branch of Chinese Society of Pathology. Expert consensus on thyroid fine needle puncture cell pathology diagnosis (2023 edition)[J]. Chin J Path, 2023, 52(5):441-446. | |
[4] | 张晓芳, 刘志艳. 2018版甲状腺细针穿刺活检细胞病理学Bethesda报告系统解读[J]. 中华病理学杂志, 2018, 47(9):729-732. |
ZHANG X F, LIU Z Y. Interpretation of the Bethesda reporting system for cellular pathology in 2018 thyroid fine needle biopsy[J]. Chin J Path, 2018, 47(9):729-732. | |
[5] | LIU C Y, CHEN C C, BYCHKOV A, et al. Constitutive cytomorphologic features of medullary thyroid carcinoma using different staining methods[J]. Diagnostics (Basel), 2021, 11(8):1396. |
[6] |
LIU C Y, BYCHKOV A, AGARWAL S, et al. Cytologic diagnosis of medullary thyroid carcinoma in the Asia-Pacific region[J]. Diagn Cytopathol, 2021, 49(1):60-69.
doi: 10.1002/dc.v49.1 URL |
[7] | 徐艳玲, 宋词, 胡平, 等. 神经内分泌肿瘤的流行现状[J]. 中华医学杂志, 2022, 102(14):1042-1046. |
XU Y L, SONG C, HU P, et al. The epidemic status of neuroendocrine tumors[J]. Natl Med J China, 2022, 102(14):1042-1046. | |
[8] | 焦琼, 刘志艳. 第3版甲状腺细针穿刺细胞病理学Bethesda报告系统解读[J]. 中华医学杂志, 2023, 103(41):3238-3244. |
JIAO Q, LIU Z Y. Interpretation of the Bethesda reporting system for thyroid fine needle puncture cell patho-logy, 3rd edition[J]. Natl Med J China, 2023, 103(41):3238-3244. | |
[9] |
ALI S Z, BALOCH Z W, COCHAND-PRIOLLET B, et al. The 2023 Bethesda system for reporting thyroid cytopathology[J]. Thyroid, 2023, 33(9):1039-1044.
doi: 10.1089/thy.2023.0141 pmid: 37427847 |
[10] |
MALEKI Z, ABRAM M, DELL'AQUILA M, et al. Insulinoma-associated protein 1 (INSM-1) expression in medullary thyroid carcinoma FNA: a multi-institutional study[J]. J Am Soc Cytopathol, 2020, 9(3):185-190.
doi: S2213-2945(20)30032-6 pmid: 32197966 |
[11] |
SEOK J Y, KANG M, DE PERALTA-VENTURINA M, et al. Diagnostic utility of INSM1 in medullary thyroid carcinoma[J]. Int J Surg Pathol, 2021, 29(6):615-626.
doi: 10.1177/1066896921995935 URL |
[12] | ASA S L, BALOCH Z W, DE KRIJGER R R. WHO classification of tumours series, endocrine and neuroendocrine tumours, 5th ed[M]. Vol. 2: Lyon (France): International Agency for Research on Cancer, 2022. |
[13] |
KIM M, KIM B H. Current guidelines for management of medullary thyroid carcinoma[J]. Endocrinol Metab (Seoul), 2021, 36(3):514-524.
doi: 10.3803/EnM.2021.1082 URL |
[14] |
ABRAHAM D T, LOW T H, MESSINA M, et al. Medullary thyroid carcinoma: long-term outcomes of surgical treatment[J]. Ann Surg Oncol, 2011, 18(1):219-225.
doi: 10.1245/s10434-010-1339-y pmid: 20878247 |
[15] |
EROVIC B M, KIM D, CASSOL C, et al. Prognostic and predictive markers in medullary thyroid carcinoma[J]. Endocr Pathol, 2012, 23(4):232-242.
doi: 10.1007/s12022-012-9225-8 pmid: 23150029 |
[16] |
HAZARD J B, HAWK W A, CRILE G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity[J]. J Clin Endocrinol Metab, 1959, 19(1):152-161.
doi: 10.1210/jcem-19-1-152 URL |
[17] |
ALZUMAILI B, XU B, SPANHEIMER P M, et al. Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome[J]. Mod Pathol, 2020, 33(9):1690-1701.
doi: 10.1038/s41379-020-0532-1 URL |
[18] |
FUCHS T L, NASSOUR A J, GLOVER A, et al. A proposed grading scheme for medullary thyroid carcinoma based on proliferative activity (Ki-67 and mitotic count) and coagulative necrosis[J]. Am J Surg Pathol, 2020, 44(10):1419-1428.
doi: 10.1097/PAS.0000000000001505 pmid: 32452872 |
[19] |
LUBIN D J, BEHRMAN D B, GOYAL S, et al. Independent validation of the international grading system for medullary thyroid carcinoma: a single institution experience[J]. Mod Pathol, 2023, 36(9):100235.
doi: 10.1016/j.modpat.2023.100235 URL |
[20] | XU B, FUCHS T L, AHMADI S, et al. International me-dullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma[J]. J Clin Oncol, 2022, 40(1):96-104. |
[21] |
NAJDAWI F, AHMADI S, CAPELLETTI M, et al. Evalua-tion of grade in a genotyped cohort of sporadic medullary thyroid carcinomas[J]. Histopathology, 2021, 79(3):427-436.
doi: 10.1111/his.v79.3 URL |
[22] |
JUNG C K, BYCHKOV A, KAKUDO K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach[J]. Endocrinol Metab (Seoul), 2022, 37(5):703-718.
doi: 10.3803/EnM.2022.1553 URL |
[23] |
BALOCH Z W, ASA S L, BARLETTA J A, et al. Overview of the 2022 WHO classification of thyroid neoplasms[J]. Endocr Pathol, 2022, 33(1):27-63.
doi: 10.1007/s12022-022-09707-3 pmid: 35288841 |
[24] |
MOURA M M, CAVACO B M, LEITE V. RAS proto-oncogene in medullary thyroid carcinoma[J]. Endocr Relat Cancer, 2015, 22(5):R235-R252.
doi: 10.1530/ERC-15-0070 URL |
[25] |
KATO S, SUBBIAH V, MARCHLIK E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients[J]. Clin Cancer Res, 2017, 23(8):1988-1997.
doi: 10.1158/1078-0432.CCR-16-1679 pmid: 27683183 |
[26] |
SMITH D P, HOUGHTON C, PONDER B A. Germline mutation of RET codon 883 in two cases of de novo MEN 2B[J]. Oncogene, 1997, 15(10):1213-1217.
doi: 10.1038/sj.onc.1201481 |
[27] | NAKAO K T, USUI T, IKEDA M, et al. Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis[J]. Head Neck, 2013, 35(12):E363-E368. |
[28] |
Ciampi R, Romei C, Ramone T, et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing[J]. iScience, 2019, 20:324-336.
doi: S2589-0042(19)30368-2 pmid: 31605946 |
[29] |
MOHAMMADI M, HEDAYATI M. A brief review on the molecular basis of medullary thyroid carcinoma[J]. Cell J, 2017, 18(4):485-492.
pmid: 28042533 |
[30] |
Anon. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Pediatrics, 2018, 142(6):e20183062.
doi: 10.1542/peds.2018-3062 URL |
[31] |
ROMEI C, CASELLA F, TACITO A, et al. New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations[J]. J Med Genet, 2016, 53(11):729-734.
doi: 10.1136/jmedgenet-2016-103833 URL |
[32] |
ROMEI C, CIAMPI R, CASELLA F, et al. RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases[J]. Oncotarget, 2018, 9(11):9875-9884.
doi: 10.18632/oncotarget.23986 pmid: 29515777 |
[33] |
ROMAN S, LIN R, SOSA J A. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases[J]. Cancer, 2006, 107(9):2134-2142.
doi: 10.1002/cncr.22244 pmid: 17019736 |
[34] |
PALAMARCHUK A, EFANOV A, MAXIMOV V, et al. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein[J]. Cancer Res, 2005, 65(24):11282-11286.
pmid: 16357133 |
[35] | 余雅玲, 刘志艳. 《CSCO甲状腺髓样癌诊疗指南2022》指南解读:遗传基因检测与遗传咨询[J]. 肿瘤预防与治疗, 2023, 36(11):931-935. |
YU Y L, LIU Z Y. Interpretation of Guidelines of Chinese Society of Clinical Oncology(CSCO) on medullary thyroid cancer:genetic testing and counseling[J]. J Cancer Control Treat, 2023, 36(11):931-935. |
[1] | 陈承坤 综述, 郭伯敏, 邓先兆, 伍波, 樊友本 审校. 甲状腺髓样癌的诊治现状[J]. 外科理论与实践, 2022, 27(03): 276-280. |
[2] | 李瑞, 刘卓然 综述, 严佶祺 审校. 正常血清降钙素和大肿块甲状腺髓样癌的研究进展[J]. 外科理论与实践, 2022, 27(03): 271-275. |
[3] | 张刚, 张哲, 张姝, 李治荣, 田武国, 黄琦, 汪玲俐, 徐琰. 遗传性甲状腺髓样癌病人RET基因型与疾病表型的关系[J]. 外科理论与实践, 2021, 26(06): 522-527. |
[4] | 林小云, 戚露月, 章振林, 岳华. 一个多发性内分泌腺瘤2A家系的临床特征与基因突变分析[J]. 诊断学理论与实践, 2020, 19(05): 481-486. |
[5] | 陈政升,陈瓅,石文暘,许彦,王斌,韩刚. 先天性手足分裂畸形的分子遗传学及基因诊断研究进展[J]. 组织工程与重建外科杂志, 2018, 14(1): 43-47. |
[6] | 王荟, 刘坤, 陈佳, 房振, 高扬, 吴丽莉. 甲状腺髓样癌细针穿刺被误诊为甲状腺乳头状癌1例报道[J]. 诊断学理论与实践, 2018, 17(03): 337-340. |
[7] | 孙团起, 王蕴珺, 吴毅,. 甲状腺癌外科诊治进展与展望[J]. 外科理论与实践, 2016, 21(04): 277-281. |
[8] | 齐研, 贾慧英,. 丙戊酸盐对甲状腺髓样癌TT细胞的影响[J]. 诊断学理论与实践, 2015, 14(03): 248-251. |
[9] | 龚进发, 陈曦,. 甲状腺髓样癌的诊治[J]. 外科理论与实践, 2014, 19(03): 195-200. |
[10] | 马维昌, 代文杰,. 遗传性甲状腺髓样癌的诊断及外科处理[J]. 外科理论与实践, 2013, 18(06): 586-589. |
[11] | 康永利, 陈曦, 姜敏, 周光文,. 血管内皮细胞生长因子受体在甲状腺髓样癌中的高表达[J]. 外科理论与实践, 2013, 18(01): 67-72. |
[12] | 宁光. 重视内分泌代谢病的基因检测[J]. 诊断学理论与实践, 2003, 2(02): 5-6. |
[13] | 马晓英,刘建民,赵咏桔,张翼飞,顾丽群,洪洁,王卫庆,宁光. RET原癌基因突变致甲状腺髓样癌一个家系的研究[J]. 诊断学理论与实践, 2003, 2(02): 26-29. |
[14] | 刘须才,王约青. 甲状腺髓样癌(附7例报告)[J]. 外科理论与实践, 1998, 3(03): 90-5. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||